STEREOISOMERS AND DRUG TOXICITY - THE VALUE OF SINGLE STEREOISOMER THERAPY

被引：38
作者：
SCOTT, AK
机构：
[1] Department of Geriatric Medicine, University of Manchester, Hope Hospital, Salford, M6 8HD, Clinical Sciences Building, Eccles Old Road
来源：
DRUG SAFETY | 1993年 / 8卷 / 02期
关键词：
D O I：
10.2165/00002018-199308020-00005
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
All drugs produce adverse effects. though the risk varies widely between different compounds. Many toxic reactions are an extension of the mechanism responsible for the therapeutic effect and can be avoided by careful dose adjustment. Other adverse events are not related to the beneficial action of the drug. Recent interest has focused on the role of the different properties of individual drug enantiomers in causing drug toxicity. For drugs with a single chiral centre, both enantiomers may be therapeutically active. However, if the main therapeutic benefit is in only 1 enantiomer, several possibilities exist for the other enantiomer - inactive, a qualitatively different effect. an antagonistic effect or greater toxicity.
引用
收藏
页码：149 / 159
页数：11
相关论文
共 36 条
[1]  
Amery A., Birkenhager W., Brixko P., Bulpitt C., Clement D., Et al., Mortality and morbidity results from the European working party on high blood pressure in the elderly trial, Lancet, 1, pp. 1349-1354, (1985)
[2]  
Baba T., Murabayashi S., Aoyagi K., Ishizaki T., Effects of dilevalol, an RR-isomer of labetalol, on blood pressure and renal function in patients with mild to moderate essential hypertension, European Journal of Clinical Pharmacology, 35, pp. 9-15, (1988)
[3]  
Breckenridge A., Which beta blocker?, British Medical Journal, 286, pp. 1085-1088, (1983)
[4]  
Campbell D.B., Stereoselectivity in clinical pharmacokinetics and drug development, European Journal of Drug Metabolism and Pharmacokinetics, 15, pp. 109-125, (1990)
[5]  
Chandler M.H.H., Scott S.R., Blouin R.A., Age-associated stereo-selective alterations in hexobarbital metabolism, Clinical Pharmacology and Therapeutics, 43, pp. 436-441, (1988)
[6]  
Choonara I.A., Cholerton S., Haynes B.P., Breckenridge A.M., Park B.K., Stereoselective interaction between the R-enantiomer of warfarin and Cimetidine, British Journal of Clinical Pharmacology, 21, pp. 271-277, (1986)
[7]  
Choonara I.A., Haynes B.P., Cholerton S., Breckenridge A.M., Park B.K., Enantiomers of warfarin and vitamin K metabolism, British Journal of Clinical Pharmacology, 22, pp. 729-732, (1986)
[8]  
Chrisp P., Goa K.L., Dilevalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension, Drugs, 39, pp. 234-263, (1990)
[9]  
Clark J.A., Zimmerman H.J., Tanner L.A., Labetalol hepatotoxicity, Annals of Internal Medicine, 113, pp. 210-213, (1990)
[10]  
Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Et al., Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension), Lancet, 338, pp. 1281-1285, (1991)
1234